FDx Advisors Inc. lowered its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 34.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,798 shares of the medical research company’s stock after selling 3,513 shares during the quarter. FDx Advisors Inc.’s holdings in IQVIA were worth $1,218,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors also recently bought and sold shares of the company. BlackRock Inc. increased its holdings in IQVIA by 4.9% in the fourth quarter. BlackRock Inc. now owns 14,826,277 shares of the medical research company’s stock valued at $2,656,421,000 after buying an additional 688,054 shares during the last quarter. State Street Corp increased its holdings in IQVIA by 1.9% in the third quarter. State Street Corp now owns 8,265,984 shares of the medical research company’s stock valued at $1,302,967,000 after buying an additional 157,447 shares during the last quarter. Great West Life Assurance Co. Can increased its holdings in IQVIA by 1,998.8% in the third quarter. Great West Life Assurance Co. Can now owns 3,187,359 shares of the medical research company’s stock valued at $25,138,000 after buying an additional 3,035,496 shares during the last quarter. Winslow Capital Management LLC increased its holdings in IQVIA by 31.5% in the third quarter. Winslow Capital Management LLC now owns 2,196,712 shares of the medical research company’s stock valued at $346,269,000 after buying an additional 525,657 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in IQVIA by 13.4% in the third quarter. Charles Schwab Investment Management Inc. now owns 929,054 shares of the medical research company’s stock valued at $146,447,000 after buying an additional 109,549 shares during the last quarter. 87.15% of the stock is currently owned by institutional investors and hedge funds.

In related news, Director John G. Danhakl bought 63,451 shares of the company’s stock in a transaction on Wednesday, December 23rd. The stock was bought at an average cost of $176.95 per share, with a total value of $11,227,654.45. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 6.00% of the stock is owned by company insiders.

Shares of NYSE:IQV opened at $190.14 on Tuesday. The company has a quick ratio of 1.12, a current ratio of 1.12 and a debt-to-equity ratio of 2.00. The company has a market cap of $36.37 billion, a P/E ratio of 208.95, a PEG ratio of 2.26 and a beta of 1.41. IQVIA Holdings Inc. has a 52 week low of $81.79 and a 52 week high of $199.99. The company has a 50-day moving average price of $186.50 and a 200 day moving average price of $170.55.

IQVIA (NYSE:IQV) last announced its quarterly earnings data on Wednesday, February 10th. The medical research company reported $2.11 EPS for the quarter, beating the Zacks’ consensus estimate of $2.00 by $0.11. The firm had revenue of $3.30 billion during the quarter, compared to the consensus estimate of $3.14 billion. IQVIA had a net margin of 1.61% and a return on equity of 18.03%. The firm’s revenue was up 13.9% compared to the same quarter last year. During the same quarter last year, the firm earned $1.74 earnings per share. Analysts expect that IQVIA Holdings Inc. will post 5.84 EPS for the current year.

IQV has been the topic of several recent analyst reports. Truist increased their target price on IQVIA from $197.00 to $235.00 in a report on Thursday, February 11th. Robert W. Baird increased their target price on IQVIA from $208.00 to $221.00 and gave the company an “outperform” rating in a report on Thursday, February 11th. Piper Sandler raised their price objective on IQVIA from $179.00 to $204.00 and gave the stock a “neutral” rating in a report on Thursday, February 11th. Morgan Stanley raised their price objective on IQVIA from $205.00 to $220.00 and gave the stock an “overweight” rating in a report on Thursday, February 11th. Finally, Mizuho raised their price objective on IQVIA from $200.00 to $210.00 and gave the stock a “buy” rating in a report on Thursday, February 11th. Three investment analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. IQVIA presently has an average rating of “Buy” and a consensus price target of $183.67.

IQVIA Profile

IQVIA Holdings Inc provides advanced analytics, technology solutions, and contract research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Featured Story: What is the cash asset ratio?

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV).

Institutional Ownership by Quarter for IQVIA (NYSE:IQV)

Receive News & Ratings for IQVIA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IQVIA and related companies with MarketBeat.com's FREE daily email newsletter.